Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBelpointe Asset Management LLC
Latest Disclosed Ownership2,776 shares
Latest Disclosed Value $ 1,239,595
Belpointe Asset Management LLC reports 33.59% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 28, 2026 - Belpointe Asset Management LLC filed a 13F-HR form disclosing ownership of 2,776 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,239,595 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 27, 2026 disclosing 4,180 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -33.59% during the quarter. The current value of the position is $1,226,270 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-28 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,776 -1,404 -33.59 1,240 -34.62 0.0452
2026-01-27 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,180 -55 -1.30 1,895 14.29 0.0685
2025-11-03 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,235 455 12.04 1,659 -1.43 0.0634
2025-07-22 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,780 -225 -5.62 1,683 -13.34 0.0701
2025-05-20 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,005 2,784 228.01 1,942 220.83 0.1010
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,221 -26 -2.09 605 4.49 0.0365
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,247 145 13.16 580 12.21 0.0348
2024-08-02 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,102 76 7.41 517 20.56 0.0360
2024-05-08 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,026 297 40.74 429 44.59 0.0321
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 729 50 7.36 297 25.42 0.0261
2023-11-15 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 679 -240 -26.12 236 -26.93 0.0245
2023-08-15 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 919 -595 -39.30 323 -32.14 0.0342
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,514 -3,351 -68.88 477 -66.10 0.0258
2023-02-08 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,865 -2,062 -29.77 1,405 -30.01 0.0849
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,927 1,593 29.87 2,006 33.38 0.1356
2022-08-02 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,334 -334 -5.89 1,504 1.69 0.1008
2022-04-28 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,668 -310 -5.19 1,479 14.56 0.0896
2022-02-15 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,978 281 4.93 1,291 24.98 0.0805
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,697 258 4.74 1,033 -5.83 0.0704
2021-08-09 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,439 897 19.75 1,097 12.40 0.0789
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,542 3,449 315.55 976 278.29 0.0835
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,093 354 47.90 258 28.36 0.0232
2020-11-13 2020-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 739 -1,259 -63.01 201 -65.34 0.0224
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,702 405
2020-07-20 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,998 296 17.39 580 43.21 0.0751
2020-07-20 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,702 -1,164 -40.61 405 -35.51 0.0709
2020-02-18 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,866 2,866 628 0.0797
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.